Yuanzhang Fang
Research Subjects
Yuanzhang Fang has a total of 136 co-authors. Here are the top co-authors by number of shared publications:
- Xinna Zhang
Department of Medical and Molecular Genetics, Indiana University School of Medicine, Indianapolis, USA
10 shared publications - Xiongbin Lu
Department of Medical and Molecular Genetics and Melvin and Bren Simon Cancer Center, Indiana University School of Medicine, Indianapolis, IN, 46202, USA
10 shared publications - Xiaoming He
Institue of Biopharmaceutical and Health Engineering, Shenzhen International Graduate School, Tsinghua University , Shenzhen, Guangdong 518055, China
9 shared publications - Chi Zhang
Department of Biomedical Engineering and Knight Cancer Institute, Oregon Health & Science University, Portland, OR 97239, USA
8 shared publications - Guang Ji
Institute of Digestive Diseases, Longhua Hospital, China-Canada Center of Research for Digestive Diseases (ccCRDD), Shanghai University of Traditional Chinese Medicine, Shanghai, China
8 shared publications - Yujing Li
Department of Medical and Molecular Genetics, Indiana University School of Medicine, Indianapolis, IN 46202, USA
8 shared publications
Latest Publications
- Open Access
- 5 March 2026
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 136  (9)
Amendment to Somatic mutation of the cohesin complex subunit confers therapeutic vulnerabilities in cancer
- 5 March 2026
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 136  (9)
Open AccessAmendment to Somatic mutation of the cohesin complex subunit confers therapeutic vulnerabilities in cancer
- Open Access
- 5 March 2026
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 136  (9)
Amendment to Atractylenolide I enhances responsiveness to immune checkpoint blockade therapy by activating tumor antigen presentation
- 5 March 2026
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 136  (9)
Open AccessAmendment to Atractylenolide I enhances responsiveness to immune checkpoint blockade therapy by activating tumor antigen presentation
- RetractionOpen Access
- 25 November 2025
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 136  (2)
Retraction for Somatic mutation of the cohesin complex subunit confers therapeutic vulnerabilities in cancer
Park jointly notified the JCI of data falsification in Supplemental Figure 8A and Supplemental Figure 9E and misconduct findings against Xiongbin Lu and Yunhua Liu. In accordance with the investigation committee's recommendation, the JCI is retracting this article.
- 25 November 2025
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 136  (2)
RetractionOpen AccessRetraction for Somatic mutation of the cohesin complex subunit confers therapeutic vulnerabilities in cancer
Park jointly notified the JCI of data falsification in Supplemental Figure 8A and Supplemental Figure 9E and misconduct findings against Xiongbin Lu and Yunhua Liu. In accordance with the investigation committee's recommendation, the JCI is retracting this article.
- RetractionOpen Access
- 25 November 2025
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 136  (2)
Retraction for Atractylenolide I enhances responsiveness to immune checkpoint blockade therapy by activating tumor antigen presentation
Park jointly notified the JCI of data falsification in Figures 2B and 6D and misconduct findings against Xiongbin Lu and Hanchen Xu. In accordance with the investigation committee's recommendation, the JCI is retracting this article.
- 25 November 2025
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 136  (2)
RetractionOpen AccessRetraction for Atractylenolide I enhances responsiveness to immune checkpoint blockade therapy by activating tumor antigen presentation
Park jointly notified the JCI of data falsification in Figures 2B and 6D and misconduct findings against Xiongbin Lu and Hanchen Xu. In accordance with the investigation committee's recommendation, the JCI is retracting this article.
- Retracted
- 17 May 2021
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 131  (10)
Atractylenolide I enhances responsiveness to immune checkpoint blockade therapy by activating tumor antigen presentation
One of the primary mechanisms of tumor cell immune evasion is the loss of antigenicity, which arises due to lack of immunogenic tumor antigens as well as dysregulation of the antigen processing machinery. In a screen for small-molecule compounds from herbal medicine that potentiate T cell–mediated cytotoxicity, we identified atractylenolide I (ATT-I), which substantially promotes tumor antigen presentation of both human and mouse colorectal cancer (CRC) cells and thereby enhances the cytotoxic response of CD8+ T cells. Cellular thermal shift assay (CETSA) with multiplexed quantitative mass spectrometry identified the proteasome 26S subunit non–ATPase 4 (PSMD4), an essential component of the immunoproteasome complex, as a primary target protein of ATT-I. Binding of ATT-I with PSMD4 augments the antigen-processing activity of immunoproteasome, leading to enhanced MHC-I–mediated antigen presentation on cancer cells. In syngeneic mouse CRC models and human patient–derived CRC organoid models, ATT-I treatment promotes the cytotoxicity of CD8+ T cells and thus profoundly enhances the efficacy of immune checkpoint blockade therapy. Collectively, we show here that targeting the function of immunoproteasome with ATT-I promotes tumor antigen presentation and empowers T cell cytotoxicity, thus elevating the tumor response to immunotherapy.
- 17 May 2021
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 131  (10)
RetractedAtractylenolide I enhances responsiveness to immune checkpoint blockade therapy by activating tumor antigen presentation
One of the primary mechanisms of tumor cell immune evasion is the loss of antigenicity, which arises due to lack of immunogenic tumor antigens as well as dysregulation of the antigen processing machinery. In a screen for small-molecule compounds from herbal medicine that potentiate T cell–mediated cytotoxicity, we identified atractylenolide I (ATT-I), which substantially promotes tumor antigen presentation of both human and mouse colorectal cancer (CRC) cells and thereby enhances the cytotoxic response of CD8+ T cells. Cellular thermal shift assay (CETSA) with multiplexed quantitative mass spectrometry identified the proteasome 26S subunit non–ATPase 4 (PSMD4), an essential component of the immunoproteasome complex, as a primary target protein of ATT-I. Binding of ATT-I with PSMD4 augments the antigen-processing activity of immunoproteasome, leading to enhanced MHC-I–mediated antigen presentation on cancer cells. In syngeneic mouse CRC models and human patient–derived CRC organoid models, ATT-I treatment promotes the cytotoxicity of CD8+ T cells and thus profoundly enhances the efficacy of immune checkpoint blockade therapy. Collectively, we show here that targeting the function of immunoproteasome with ATT-I promotes tumor antigen presentation and empowers T cell cytotoxicity, thus elevating the tumor response to immunotherapy.
- 4 January 2021
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 131  (1)
MAL2 drives immune evasion in breast cancer by suppressing tumor antigen presentation
Immune evasion is a pivotal event in tumor progression. To eliminate human cancer cells, current immune checkpoint therapy is set to boost CD8+ T cell–mediated cytotoxicity. However, this action is eventually dependent on the efficient recognition of tumor-specific antigens via T cell receptors. One primary mechanism by which tumor cells evade immune surveillance is to downregulate their antigen presentation. Little progress has been made toward harnessing potential therapeutic targets for enhancing antigen presentation on the tumor cell. Here, we identified MAL2 as a key player that determines the turnover of the antigen-loaded MHC-I complex and reduces the antigen presentation on tumor cells. MAL2 promotes the endocytosis of tumor antigens via direct interaction with the MHC-I complex and endosome-associated RAB proteins. In preclinical models, depletion of MAL2 in breast tumor cells profoundly enhanced the cytotoxicity of tumor-infiltrating CD8+ T cells and suppressed breast tumor growth, suggesting that MAL2 is a potential therapeutic target for breast cancer immunotherapy.
- 4 January 2021
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 131  (1)
MAL2 drives immune evasion in breast cancer by suppressing tumor antigen presentation
Immune evasion is a pivotal event in tumor progression. To eliminate human cancer cells, current immune checkpoint therapy is set to boost CD8+ T cell–mediated cytotoxicity. However, this action is eventually dependent on the efficient recognition of tumor-specific antigens via T cell receptors. One primary mechanism by which tumor cells evade immune surveillance is to downregulate their antigen presentation. Little progress has been made toward harnessing potential therapeutic targets for enhancing antigen presentation on the tumor cell. Here, we identified MAL2 as a key player that determines the turnover of the antigen-loaded MHC-I complex and reduces the antigen presentation on tumor cells. MAL2 promotes the endocytosis of tumor antigens via direct interaction with the MHC-I complex and endosome-associated RAB proteins. In preclinical models, depletion of MAL2 in breast tumor cells profoundly enhanced the cytotoxicity of tumor-infiltrating CD8+ T cells and suppressed breast tumor growth, suggesting that MAL2 is a potential therapeutic target for breast cancer immunotherapy.
- Open Access
- 7 May 2020
- Published by American Society for Clinical Investigation in JCI Insight
- Vol. 5  (9)
ST2 as checkpoint target for colorectal cancer immunotherapy
Immune checkpoint blockade immunotherapy delivers promising clinical results in colorectal cancer (CRC). However, only a fraction of cancer patients develop durable responses. The tumor microenvironment (TME) negatively impacts tumor immunity and subsequently clinical outcomes. Therefore, there is a need to identify other checkpoint targets associated with the TME. Early-onset factors secreted by stromal cells as well as tumor cells often help recruit immune cells to the TME, among which are alarmins such as IL-33. The only known receptor for IL-33 is stimulation 2 (ST2). Here we demonstrated that high ST2 expression is associated with poor survival and is correlated with low CD8 + T cell cytotoxicity in CRC patients. ST2 is particularly expressed in tumor-associated macrophages (TAMs). In preclinical models of CRC, we demonstrated that ST2-expressing TAMs (ST2 + TAMs) were recruited into the tumor via CXCR3 expression and exacerbated the immunosuppressive TME; and that combination of ST2 depletion using ST2 -KO mice with anti–programmed death 1 treatment resulted in profound growth inhibition of CRC. Finally, using the IL-33trap fusion protein, we suppressed CRC tumor growth and decreased tumor-infiltrating ST2 + TAMs. Together, our findings suggest that ST2 could serve as a potential checkpoint target for CRC immunotherapy.
- 7 May 2020
- Published by American Society for Clinical Investigation in JCI Insight
- Vol. 5  (9)
Open AccessST2 as checkpoint target for colorectal cancer immunotherapy
Immune checkpoint blockade immunotherapy delivers promising clinical results in colorectal cancer (CRC). However, only a fraction of cancer patients develop durable responses. The tumor microenvironment (TME) negatively impacts tumor immunity and subsequently clinical outcomes. Therefore, there is a need to identify other checkpoint targets associated with the TME. Early-onset factors secreted by stromal cells as well as tumor cells often help recruit immune cells to the TME, among which are alarmins such as IL-33. The only known receptor for IL-33 is stimulation 2 (ST2). Here we demonstrated that high ST2 expression is associated with poor survival and is correlated with low CD8 + T cell cytotoxicity in CRC patients. ST2 is particularly expressed in tumor-associated macrophages (TAMs). In preclinical models of CRC, we demonstrated that ST2-expressing TAMs (ST2 + TAMs) were recruited into the tumor via CXCR3 expression and exacerbated the immunosuppressive TME; and that combination of ST2 depletion using ST2 -KO mice with anti–programmed death 1 treatment resulted in profound growth inhibition of CRC. Finally, using the IL-33trap fusion protein, we suppressed CRC tumor growth and decreased tumor-infiltrating ST2 + TAMs. Together, our findings suggest that ST2 could serve as a potential checkpoint target for CRC immunotherapy.
- RetractedOpen Access
- 9 November 2018
- Published by Springer Nature in Nature Communications
- Vol. 9  (1) , 1-16
RETRACTED ARTICLE: Targeting 17q23 amplicon to overcome the resistance to anti-HER2 therapy in HER2+ breast cancer
Chromosome 17q23 amplification occurs in ~11% of human breast cancers. Enriched in HER2+ breast cancers, the 17q23 amplification is significantly correlated with poor clinical outcomes. In addition to the previously identified oncogene WIP1 , we uncover an oncogenic microRNA gene, MIR21 , in a majority of the WIP1 -containing 17q23 amplicons. The 17q23 amplification results in aberrant expression of WIP1 and miR-21, which not only promotes breast tumorigenesis, but also leads to resistance to anti-HER2 therapies. Inhibiting WIP1 and miR-21 selectively inhibits the proliferation, survival and tumorigenic potential of the HER2+ breast cancer cells harboring 17q23 amplification. To overcome the resistance of trastuzumab-based therapies in vivo, we develop pH-sensitive nanoparticles for specific co-delivery of the WIP1 and miR-21 inhibitors into HER2+ breast tumors, leading to a profound reduction of tumor growth. These results demonstrate the great potential of the combined treatment of WIP1 and miR-21 inhibitors for the trastuzumab-resistant HER2+ breast cancers.
- 9 November 2018
- Published by Springer Nature in Nature Communications
- Vol. 9  (1) , 1-16
RetractedOpen AccessRETRACTED ARTICLE: Targeting 17q23 amplicon to overcome the resistance to anti-HER2 therapy in HER2+ breast cancer
Chromosome 17q23 amplification occurs in ~11% of human breast cancers. Enriched in HER2+ breast cancers, the 17q23 amplification is significantly correlated with poor clinical outcomes. In addition to the previously identified oncogene WIP1 , we uncover an oncogenic microRNA gene, MIR21 , in a majority of the WIP1 -containing 17q23 amplicons. The 17q23 amplification results in aberrant expression of WIP1 and miR-21, which not only promotes breast tumorigenesis, but also leads to resistance to anti-HER2 therapies. Inhibiting WIP1 and miR-21 selectively inhibits the proliferation, survival and tumorigenic potential of the HER2+ breast cancer cells harboring 17q23 amplification. To overcome the resistance of trastuzumab-based therapies in vivo, we develop pH-sensitive nanoparticles for specific co-delivery of the WIP1 and miR-21 inhibitors into HER2+ breast tumors, leading to a profound reduction of tumor growth. These results demonstrate the great potential of the combined treatment of WIP1 and miR-21 inhibitors for the trastuzumab-resistant HER2+ breast cancers.
- RetractedOpen Access
- 22 October 2018
- Published by Springer Nature in Nature Communications
- Vol. 9  (1) , 1-15
RETRACTED ARTICLE: Heterozygous deletion of chromosome 17p renders prostate cancer vulnerable to inhibition of RNA polymerase II
Heterozygous deletion of chromosome 17p (17p) is one of the most frequent genomic events in human cancers. Beyond the tumor suppressor TP53 , the POLR2A gene encoding the catalytic subunit of RNA polymerase II (RNAP2) is also included in a ~20-megabase deletion region of 17p in 63% of metastatic castration-resistant prostate cancer (CRPC). Using a focused CRISPR-Cas9 screen, we discovered that heterozygous loss of 17p confers a selective dependence of CRPC cells on the ubiquitin E3 ligase Ring-Box 1 (RBX1). RBX1 activates POLR2A by the K63-linked ubiquitination and thus elevates the RNAP2-mediated mRNA synthesis. Combined inhibition of RNAP2 and RBX1 profoundly suppress the growth of CRPC in a synergistic manner, which potentiates the therapeutic effectivity of the RNAP2 inhibitor, α-amanitin-based antibody drug conjugate (ADC). Given the limited therapeutic options for CRPC, our findings identify RBX1 as a potentially therapeutic target for treating human CRPC harboring heterozygous deletion of 17p.
- 22 October 2018
- Published by Springer Nature in Nature Communications
- Vol. 9  (1) , 1-15
RetractedOpen AccessRETRACTED ARTICLE: Heterozygous deletion of chromosome 17p renders prostate cancer vulnerable to inhibition of RNA polymerase II
Heterozygous deletion of chromosome 17p (17p) is one of the most frequent genomic events in human cancers. Beyond the tumor suppressor TP53 , the POLR2A gene encoding the catalytic subunit of RNA polymerase II (RNAP2) is also included in a ~20-megabase deletion region of 17p in 63% of metastatic castration-resistant prostate cancer (CRPC). Using a focused CRISPR-Cas9 screen, we discovered that heterozygous loss of 17p confers a selective dependence of CRPC cells on the ubiquitin E3 ligase Ring-Box 1 (RBX1). RBX1 activates POLR2A by the K63-linked ubiquitination and thus elevates the RNAP2-mediated mRNA synthesis. Combined inhibition of RNAP2 and RBX1 profoundly suppress the growth of CRPC in a synergistic manner, which potentiates the therapeutic effectivity of the RNAP2 inhibitor, α-amanitin-based antibody drug conjugate (ADC). Given the limited therapeutic options for CRPC, our findings identify RBX1 as a potentially therapeutic target for treating human CRPC harboring heterozygous deletion of 17p.
- RetractedOpen Access
- 4 June 2018
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 128  (7) , 2951-2965
Somatic mutation of the cohesin complex subunit confers therapeutic vulnerabilities in cancer
A synthetic lethality–based strategy has been developed to identify therapeutic targets in cancer harboring tumor-suppressor gene mutations, as exemplified by the effectiveness of poly ADP-ribose polymerase (PARP) inhibitors in BRCA1/2-mutated tumors. However, many synthetic lethal interactors are less reliable due to the fact that such genes usually do not perform fundamental or indispensable functions in the cell. Here, we developed an approach to identifying the “essential lethality” arising from these mutated/deleted essential genes, which are largely tolerated in cancer cells due to genetic redundancy. We uncovered the cohesion subunit SA1 as a putative synthetic-essential target in cancers carrying inactivating mutations of its paralog, SA2. In SA2-deficient Ewing sarcoma and bladder cancer, further depletion of SA1 profoundly and specifically suppressed cancer cell proliferation, survival, and tumorigenic potential. Mechanistically, inhibition of SA1 in the SA2-mutated cells led to premature chromatid separation, dramatic extension of mitotic duration, and consequently, lethal failure of cell division. More importantly, depletion of SA1 rendered those SA2-mutated cells more susceptible to DNA damage, especially double-strand breaks (DSBs), due to reduced functionality of DNA repair. Furthermore, inhibition of SA1 sensitized the SA2-deficient cancer cells to PARP inhibitors in vitro and in vivo, providing a potential therapeutic strategy for patients with SA2-deficient tumors.
- 4 June 2018
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 128  (7) , 2951-2965
RetractedOpen AccessSomatic mutation of the cohesin complex subunit confers therapeutic vulnerabilities in cancer
A synthetic lethality–based strategy has been developed to identify therapeutic targets in cancer harboring tumor-suppressor gene mutations, as exemplified by the effectiveness of poly ADP-ribose polymerase (PARP) inhibitors in BRCA1/2-mutated tumors. However, many synthetic lethal interactors are less reliable due to the fact that such genes usually do not perform fundamental or indispensable functions in the cell. Here, we developed an approach to identifying the “essential lethality” arising from these mutated/deleted essential genes, which are largely tolerated in cancer cells due to genetic redundancy. We uncovered the cohesion subunit SA1 as a putative synthetic-essential target in cancers carrying inactivating mutations of its paralog, SA2. In SA2-deficient Ewing sarcoma and bladder cancer, further depletion of SA1 profoundly and specifically suppressed cancer cell proliferation, survival, and tumorigenic potential. Mechanistically, inhibition of SA1 in the SA2-mutated cells led to premature chromatid separation, dramatic extension of mitotic duration, and consequently, lethal failure of cell division. More importantly, depletion of SA1 rendered those SA2-mutated cells more susceptible to DNA damage, especially double-strand breaks (DSBs), due to reduced functionality of DNA repair. Furthermore, inhibition of SA1 sensitized the SA2-deficient cancer cells to PARP inhibitors in vitro and in vivo, providing a potential therapeutic strategy for patients with SA2-deficient tumors.